Venture capital

While it is not a perfect indicator, it sometimes helps to keep track of how often VCs refer to their portfolio companies as deals. If they never describe their investments in scientific or human terms, they are pure money managers with no personal commitment to the success or failure of the ventures. 

---

The overall competitiveness of the industries in Europe, Japan and the USA can be regarded as equivalent. But the better access to venture capital in the USA, and also in Canada, can give these countries an advantage, especially in developing innovative small and mediumsized companies. 

Gene Kleiner was one of the truly wise men of Silicon Valley, having co-founded Fairchild Semiconductor, as well as Kleiner Perkins, an incredibly successful venture capital firm. What Kleiner s First Law teaches is that biotech companies should raise capital whenever they can, assuming the deals do not have fatal flaws (as will be discussed below). I once... 

Postmoney value is the market cap after the funding is complete and is what new investors focus on. Postmoney value is measured against other deals and the likely step-up in value prior to the next funding evenf. As the biotech market heats up or cools down, comparable values rise and fall. During the venture capital stage, investors try to estimate when the company can do an IPO (their exit strategy) and at what premoney value, and based on this estimate, coupled with their target rate of refum, they discount back to what would be a reasonable private postmoney value. 

UPS s entrepreneurial activities are driven by its venture capital fund and alliances with universities and partners. Here UPS understands that... 

In parallel, the team built up an entrepreneurial infrastructure, consisting of an intellectual property network, a venture capital network, and a business network. The intellectual property network was designed to provide a steady flow of technologies and products that could serve as the basis of an enterprise. Says Neo ... 

Pharmaceutical companies spent on average 15% of their sales on Research Development (R D). For biotech companies this figure is (sometimes much) higher. It should be realized that many biotech companies do not have sales yet and are financed by the income from joint ventures with major pharmaceutical companies, or by venture capital. 

Venture capital also plays a role in Denmark. The Danish manufacturing company Danfoss A/S has recently joined the Conduit Ventures Limited, the first European based venture capital company, which focuses purely upon fuel cells and related hydrogen technologies. Danfoss A/S has added US 5 million to the fund. 

Virtual pharma 4000- 5000 Venture capital funded, 1-2 developmental drugs, mainly biopharmaceuticals, small R D, no production, no M S organization Cell Therapeutics, Gilead, Trimeris, Vertex, USA Alizyme, UK Morphosys, Germany Actelion, Speedel, Switzerland... 

---